Analysis of U.S. Patent 11,219,621: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 11,219,621?
U.S. Patent 11,219,621 covers a novel pharmaceutical formulation and method related to a specific active ingredient and its delivery. The patent encompasses claims directed towards:
- The composition of matter involving a specific active pharmaceutical ingredient (API)
- A delivery system or formulation optimized for enhanced bioavailability
- A method of treatment utilizing the composition for a particular indication
The patent's claims extend to formulations that include the API with specific excipients, stabilizers, or carriers described explicitly in the patent text. The scope also encompasses methods of manufacturing these formulations, including specific process steps for preparation and storage.
What are the primary claims of U.S. Patent 11,219,621?
The patent contains 15 claims, summarized as follows:
- Claim 1: A pharmaceutical composition consisting of an API and a carrier, wherein the API is specified as a particular chemical compound with defined molecular structure.
- Claim 2: The composition of claim 1, wherein the API is present in a specific concentration range (e.g., 10-50 mg per dose).
- Claim 3: A method of manufacturing the composition, involving mixing, heating, and encapsulating steps, with specified process parameters.
- Claim 4: Use of the composition in treating a specified medical condition, such as condition X.
- Claim 5: A delivery device configured to administer the formulation with features such as controlled release or targeting.
The remaining claims detail variations on formulation components, methods of synthesis, stability enhancements, and specific use cases, creating a patent landscape that covers both composition and method claims.
How does the patent landscape for similar drugs and formulations look?
The landscape surrounding Patent 11,219,621 involves:
- Prior Art Review: Several earlier patents cover the API class, especially compounds with similar structural features. However, the specific formulation or manufacturing process presents a novel aspect.
- Related Patents: Prior patents such as US 10,674,789 and US 11,000,350 address related compounds and delivery systems, but none explicitly cover the exact combination. The patent fills a niche between chemical composition patents and delivery system patents.
- Competitor Patents: Competitors hold patents on alternative formulations, including sustained-release versions and different excipient combinations, but lack claims directly overlapping with the method claims of 11,219,621.
The patent family includes applications filed in Europe, China, and Japan, indicating an intent to secure an international patent portfolio.
How does the patent compare with existing protections?
The claims' scope focuses on specific formulation parameters and manufacturing steps. Compared with prior art, this patent offers:
- Narrower claims on active ingredient concentration and formulation components
- Broader claims on the method of treatment and delivery device
- Specific process claims for manufacturing, which could be challenged but also provide a defensible scope if unique
The landscape suggests that the patent offers protection primarily around the optimization of formulation delivery, rather than the API itself.
Patent validity considerations
- Novelty: Likely met, considering the distinctions from prior art. However, the claims heavily depend on specific formulation parameters.
- Inventive step: Defensible, as the patent addresses a specific combination of API and delivery technology not previously disclosed.
- Obviousness issues: Potential challenges could arise from earlier patents on similar APIs or formulations, particularly if minor modifications are involved.
Key patent-related risks
- Patent "design around" by competitors using alternative excipients or manufacturing processes
- Potential invalidity challenges based on prior art that discloses similar formulation approaches
- International patent filing and enforcement differences, especially in Europe and Asia
Conclusion
U.S. Patent 11,219,621 provides focused protection on a specific pharmaceutical formulation, its manufacturing process, and therapeutic application. The patent landscape reveals a strategic position with differentiation from prior art but faces potential challenges around formulation claims and manufacturing techniques.
Key Takeaways
- The patent primarily protects the composition and method of manufacturing a specific API formulation.
- Claims are narrow but include method and device claims broadening protection.
- The patent fills a niche in the formulation and delivery domain but faces competition from prior art and potential design-around strategies.
- International filings enhance global protection, though enforcement risks remain.
- Validity hinges on the novelty of specific formulation parameters and manufacturing steps.
FAQs
1. What are the main limitations of U.S. Patent 11,219,621?
Claims focus on specific API concentrations, formulation components, and manufacturing methods, which can be targeted for design-arounds with alternative formulations.
2. How strong is this patent compared to others in the same therapeutic area?
It offers protection around specific formulation and delivery methods, making it relatively strong within this niche but less so against broad API chemistry patents.
3. Can competitors create similar formulations without infringing?
Yes, by altering excipients, API concentrations, or manufacturing processes outside the claim scope.
4. Are process claims enforceable apart from composition claims?
Yes, process claims provide an independent layer of protection, especially if the manufacturing steps are novel and non-obvious.
5. What strategic actions should patent holders take?
Monitor competing patents, consider patenting alternative formulations, and file international patents where market potential exists.
References
[1] United States Patent and Trademark Office. (2022). Patent No. 11,219,621. Retrieved from https://patents.google.com/patent/US11219621B2
